Novartis to lay off 8,000 jobs worldwide. The Swiss pharmaceutical company announced plans to cut 8,000 jobs, or 7% of its workforce, in a bid to save USD 1 billion. The layoffs will affect employees across all levels and functions, and will be implemented over the next two years.
Novartis receives positive CHMP opinion for multiple sclerosis biosimilar natalizumab. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Novartis's biosimilar natalizumab, which is used to treat multiple sclerosis.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5223
Published Date: Sep 07, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing investment in pharmaceutical infrastructure is the major factor driving the market growth.
The market size of controlled substance API is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are Pfizer Inc., Johnson & Johnson, Novartis AG, Roche Holding AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, and others.
The pharmaceuticals segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in the Asia Pacific region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.